Published online before print January 30, 2003, doi: 10.1161/01.STR.0000056527.34434.59
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:764.)
© 2003 American Heart Association, Inc.
Original Contributions |
Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human Platelets
In Vitro and In Vivo/Ex Vivo Studies
From the Institute for Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg, Wuerzburg, Germany.
Correspondence to Ulrich Walter, MD, Institute for Clinical Biochemistry and Pathobiochemistry, University of Wuerzburg, Josef-Schneider Strasse 2, D-97080 Wuerzburg, Germany. E-mail uwalter{at}klin-biochem.uni-wuerzburg.de
Background and Purpose— Dipyridamole and in particular dipyridamole in combination with low-dose aspirin are very effective in preventing recurrent stroke. However, the mechanism(s) underlying this dipyridamole effect have not been elucidated. Since dipyridamole inhibits the cGMP-specific phosphodiesterase type V in vitro, we hypothesized and tested whether therapeutically relevant dipyridamole concentrations enhance NO/cGMP-mediated effects in intact human platelets studied ex vivo.
Methods— Phosphorylation of vasodilator-stimulated phosphoprotein (VASP), an established marker of NO/cGMP effects in human platelets, was quantified by phosphorylation-specific antibodies and Western blots. Serotonin secretion and thromboxane synthase activity were determined by fluorometric quantification of derivatized serotonin and synthase products, respectively.
Results— Endothelium-derived factors such as NO and prostaglandin I2 are known to elevate both cGMP and cAMP levels with concomitant platelet inhibition and VASP phosphorylation. In our in vitro experiments, therapeutically relevant concentrations (3.5 µmol/L) of dipyridamole amplified only cGMP-mediated VASP phosphorylation due to the NO donor sodium nitroprusside, but not cAMP-mediated effects. Furthermore, thromboxane synthase activity and serotonin secretion, events important for initial platelet activation, were inhibited by sodium nitroprusside, an effect also enhanced by dipyridamole, demonstrating the functional relevance of these observations. Finally, the ex vivo enhancement of NO/cGMP effects was also observed with platelets obtained from healthy volunteers treated with extended-release dipyridamole.
Conclusions— Under therapeutically relevant conditions, dipyridamole enhances platelet inhibition by amplifying the signaling of the NO donor sodium nitroprusside. These data support the concept that enhancement of endothelium-dependent NO/cGMP-mediated signaling may be an important in vivo component of dipyridamole action.
Key Words: dipyridamole • phosphodiesterase inhibitors • platelet aggregation inhibitors • stroke
This article has been cited by other articles:
 |
|
 |
|
  J. E. Freedman Oxidative Stress and Platelets Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s11 - s16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-H. Kim and J. K. Liao Translational Therapeutics of Dipyridamole Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s39 - s42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chakrabarti, O. Vitseva, D. Iyu, S. Varghese, and J. E. Freedman The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 494 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Begonja, S. Gambaryan, J. Geiger, B. Aktas, M. Pozgajova, B. Nieswandt, and U. Walter Platelet NAD(P)H-oxidase-generated ROS production regulates {alpha}IIb{beta}3-integrin activation independent of the NO/cGMP pathway Blood, October 15, 2005; 106(8): 2757 - 2760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gamboa, R. Abraham, A. Diedrich, C. Shibao, S. Y. Paranjape, G. Farley, and I. Biaggioni Role of Adenosine and Nitric Oxide on the Mechanisms of Action of Dipyridamole Stroke, October 1, 2005; 36(10): 2170 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Weyrich, M. M. Denis, J. R. Kuhlmann-Eyre, E. D. Spencer, D. A. Dixon, G. K. Marathe, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet-Monocyte Aggregates Circulation, February 8, 2005; 111(5): 633 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jedlitschky, K. Tirschmann, L. E. Lubenow, H. K. Nieuwenhuis, J. W. N. Akkerman, A. Greinacher, and H. K. Kroemer The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage Blood, December 1, 2004; 104(12): 3603 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gambaryan, J. Geiger, U. R. Schwarz, E. Butt, A. Begonja, A. Obergfell, and U. Walter Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase Blood, April 1, 2004; 103(7): 2593 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Feil, S. M. Lohmann, H. de Jonge, U. Walter, and F. Hofmann Cyclic GMP-Dependent Protein Kinases and the Cardiovascular System: Insights From Genetically Modified Mice Circ. Res., November 14, 2003; 93(10): 907 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF]
|
|